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Preparations of N-[3-(hetero)aryl-aminocarbonyl]propanoyl-
-L-proline derivatives 12, 13, 22 and 23 are described. A novel 
approach consists of fusing (80-100 °C) N-(hetero)aryl-succinimides 
(7, 8, 20, 21) with unprotected L-proline and imidazole in the pre-
sence of dimethylformamide. In vitro tests for angiotensin con-
verting enzyme (ACE) inhibition showed that all N-(arylamino-
carbonyl)-propanoyl-L-prolines (12, 13, 22 and 23) exhibit lower 
activity than captopril (1), their IC50's ranging from 2.5 X 10-4 to 
3.3 X 10-3 M. 
INTRODUCTION 
Angiotensin converting enzyme (ACE) inhibitors show promise in the 
treatment of hypertension.1- 3A very potent ACE inhibitor captopril (1; N-(3-
-mercapto-2-methylpropanoyl)-L-proline; SQ 14225) has been introduced into 
the therapy of various forms of renovascular hypertension.4- 6 The first clinical 
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However, chronic oral administration of this inhibitor caused a number of 
side effects.1- 9 Some of them most probably were due to the well documented 
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ability of captopril to reduce S-S bridges and thus alter some peptides and 
proteins in vitro and in vivo.10, 11 This stimu1ated the search for ACE inhibitors 
without free SH-groups.12,13 
On the other ha:nd, it was recently argued14 that the renin-angiotensin 
system (RAS) in the brain participates in the control of blood pressure. It was 
found15 that prolonged oral treatment with captopril was followed by an 
increase in ACE activity in blood-pressure-controlling brain regions. Also, 
when captopril was injected into the cerebral ventricles in spontaneously 
hypertensive rats, it produced a decrease in blood pressure. The decrease was 
greater than that produced by the same dose of captopril given i. v.16 The 
hypothesis was put forward that captopril crosses the blood-brain barrier and 
reaches brain sites of high RAS activity as part of its blood pressure lowering 
effect. 
All the above data prompted us to develop a working hypothesis, that 
certain substances which can easily pass the blood-brain barrier, and which 
possess a certain intrinsic ACE i·nhibitory activity, would exert a higher anti-
hypertensive effect than cap1Jopril (or other peptide-like derivatives devoid of 
lipophilic properties), by reaching brain sites of high RAS activity. The 
absence of a throl group in such compounds might be an additional advantage 
in eliminating the possible in vivo side effects mentioned earlier. 
Two pairs of compounds, 12 and 13, and 22 and 23, respectively, were 
designated as potential ACE inhibitors on the basis of the following rationales 
It is know that 2-amino-benzophenone derivatives 2, bearing one to three 
a-aminoacid residues on the 2-amino group, exhibit strong regulatory effects 
on the central nervous system.17-19 Since the benzophenone moiety in 2 
(R' = H) exists in vivo only temporarily cyclising into 1,4-benzodiazepines,1; 
the N-peptidyl moiety in 2 (R' = one or two a-aminoacyl res1dues) acts as a 
lipophilic carrier for dipeptides and tripeptides. A benzophenone derivative of 
y-aminobutyramide has recently been designated as the carrier of the latter 
into the CNs.20 
Having these results in mind, along with the documented activity of 
N-succinyl proline,5 we chose 12 and 13 as the target molecules. In these 
compounds benzophenone and L-proline subunits are linked by the succinic 
bridge. The second pair (compounds 22 and 23) contains the 2-aminopyridyl 
moiety and its N-oxide, respectively, which were expected to act as ligands 
for Zn(II) ions present at the active site of ACE.21 7-Membered chelates with 
divalent metal ions are well known models for the active sites of urease22 
and hydrolases.23 Although no direct extrapolation of the results with similar 
ligands and different metal ions can be made, certain chelating properties of 
the N-oxide subunit in 23 may be expected. · 
RESULTS AND DISCUSSION 
All target compounds were approached in two different ways. The first 
made use of classical, dicyclohexylcarbodiimide (DCC)- promoted condensation 
of carboxy derivatives 5, 6, 18 and 19 with the benzylester of L-proline. The 
reaction rendered some difficulties with 18 and 19, because of their poor 
solubility. Only dimethylformamide (DMF) proved to be applicable, but limited 
solubility even in this solvent required reaction times of up to several days. 
This caused a known side reaction, i.e. the formation of N-acyl-N,N'-dicy-
-:lohexyl-urea derivatives 26 and 27 which were separated acnd characterized. 
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Hydrogenolysis of the intermediary benzyl-esters (14, 15, 24 and 25) afforded 
the free carboxylic acid derivatives in rather low yields, the loss of material 
being mainly due to adsorption onto the catalyst. 
A method of direct acylation of unprotected L.-proline was elaborated 



























and 6 using a slight molar excess of thionyl chloride in tetrahydrofuran (THF) 
at ambient temperature led to quantitative cyclisation to give 7 and 8. A 
precedent to this reaction was described by Rudinger,24 i.e. cyclisation of 
N-tosyl-glutamic acid into N-tosyl-pyroglutamic acid, the latter behaving as 
a nucleophile.24 This observation prompted us to examine the acylating pro-
perties of 7. On heating with benzylamine and piperidine in an inert solvent, 
7 afforded 9 and 10 in 620/o and 790/o yield, respectively. It is interesting to note 
that the methylene congeners of 7, i. e. compounds A, were claimed25 to provide 
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L-proline with 7 was attempted in aqueous solution, only hydrolysis was 
noticed. This is in contrast to Ne:flken's finding26 ,27 that the N-ethoxycarbonyl-
-imide 28 could N-acylate sodium salts of a-am~no acids in aqueous solution 
affording a-N,N-phtalimido acids. 
In spite of the vinylogous acyl-amide character of 7 (formulae B and C) 
this compound did not react as an acylating agent, although acylation with 
N-acyloxy-succinimides (D) has been observed.28 Adding traces of hydrngen 
chloride or sodium methoxide in methanol 7 gave methylester 16, whereby 
the base catalysed solvolytic reaction proceeded much more cleanly than the 
acid-catalysed one. 
0 0 0 0 
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On the basis of the above finding we tried the acylation of L-proline in 
the presence of a strong base, imidazole, in the absence of any solvent. Fusion 
of a mixture of 7, L-proline and imidazole in excess afforded a clear melt 
already at 90-100 °C. TLC control indicated formation of 15. Prolonged heating 
led to decarboxylation into 17. Somewhat higher yeilds of 22 and 23 were 
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obtained when DMF was added to assure homogenization at 80-90 °C. Limited 
racemization, if at all, occurred under the above conditions, as unequivocally 
proved by comparison of [a]o's with those of compounds 12, 13, 22 and 23 
prepared via the DCC/imidazole method (Table I). 
TABLE I 





12' -49.7° -55.8° 
13' -47.6° -48.5° 
22" -69.QO -86.3° 
23" -64.5° -69.0° 
n Determined in CHC13; " Determined in MeOH; c c = 0.98 - 1.05 for both solvents. 
Wj!th regard to the possible mechanism of acylation of L-proline with aryl-
-succinimides in the presence of imidazole, some control experiments were 
performed. Thus, heating of 20 and imidaZ'Ole (ca. 200/o total concentration in 
DMF-d7) in the NMR instrument up to 140 °c did not result in the formation 
of N-acyl-imidazole. NMR spectra of the reaction components remained 
unchanged, while a TLC control confirmed their presence as the only com-
pounds in the solution. Thus, N-acylimidazole could safely be excluded as an 
activated intermediate. On the other hand, heating of 20 and L-proline in 
DMF-d7, in the absence iof imidazole, resulted in slow dissappearance of 20 
above 125-130 °C, and formation of 22 and another ' product with higher R1. 
The NMR spectra revealed accumulation of the multiplet between 1.7-2.7 ppm. 
The second product was concluded to be decarboxylated 22, analogous 
characteristics were exhibited by its congener 17, (see Experimental). However, 
when 20, imidazole, and L-proline (mol. ratio 1 : 2 : 1, total concn. ca. 25°/a) 
were heated in DMF-d7 at 100-110 °c for 30 min to 1 h, NMR spectra revealed 
predominant formation of 22, while traces of its decarboxylation product were 
visible on TLC. These experiments proved that imidazole did not form an 
active intermediate, but rather acted as a strong base, as well as a strong 
hydrogen donor, hindering protonation of the proline amino group and activa-
ting N-aryl succinimide by hydrogen bonding to its carbonyl group. A similar 
role of the imidazole ring is well established in various biological and non-
-biological systems. 29 
Examination of in vitro ACE inhibitory activities of compounds 12, 13, 
22 and 23 revealed that they are inferior to captopril (Table II). At the same 
time they were also shown to be poor inhibitors of leucine aminopeptidase 
(LAP) and to inhibit no other examined enzymes (Table III). 
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TABLE II 








2.45 x 10-~ 
5.70 x 10-4 
2.47 x 10-3 
3.33 x 10-3 
2.57 X 10-s 
• All values are the average results obtained in three or more experiments. 
TABLE III 
Inhibition of Some Other Proteolytic Enzymes 
Enzyme Inhibition (O/o)* 12 13 22 
Leucine aminopeptidase 42 46 11 
Cathepsin B 0 0 0 
Cathepsin H 13 
a-Chymotrypsin 0 0 0 
Trypsin 0 0 0 
Elastase 0 0 0 







The presented results indicate that the lipophilic berr2lophenone group has 
an unfa\norable fit for binding on the enzyme. Newly introduced potential 
bidentate ligands have a lower ability to complex Zn ion at the active site 
than the thiol or carhoxylic group. Steric hindrance, however, does not seem 
to be a dominant drawback since compounds 12 and 13 with more bulky 
residues are better inhibitors than compounds 22 and 23 with the pyridine 
ring at that position. The same difference in inhibitory activity. between the 
two pairs has been observed with LAP, which is also a metallo-protease with 
Zn at the active site. 
EXPERIMENTAL 
Melting points were determined on electrothermal melting point apparatus and 
have not been corrected. IR spectra (KBr pellets, if not stated otherwise) were 
obtained with a Perkin Elmer M 297 spectrophotometer (only strong bands are 
indicated). 1H NMR spectra were run on a JEOL FX-90Q (90 MHz) spectrophotometer 
with TMS as internal standard; shifts are given in ppm values downfield from 
TMS. Optical rotations were measured on a Zeiss-Winkel instrument at ambient 
temperature. Thin layer chromatography (TLC) was performed on aluminium plates 
precoated with Merck silica gel 60 F254. Column chromatography was run over gra-
nular silica gel 0.05- 0.20 mm (Merck). Organic extracts were regularly dried over 
Na2S04 and evaporated in vacuo. 
Benzylester of L-proline was prepared in 780/o yield using a modified procedure 
of Patel,29 ,30 that mainly consists in performing the reaction at O oc for 4 h and over-
night at ambient temperature, isolating a product by dilution with ether (1 : 3) 
and slow crystallization on ice. Compounds 3 and 4 were purchased from Fluka, 
compounds 18 and 20 were prepared according to ref. 31. 
General Procedure for Preparation of N-3'-carboxypropanoyl-arylamines 
5 and 6 
Amine 3 or 4 (0.05 mole) and succinic anhydride (0.055 mole) were heated in 
toluene (60 ml) under reflux for 1 h. The reaction mixture was allowed to cool to 
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ambient temperature, then it was chilled on ice overnight. The crude product was 
collected on a filter, washed with light petroleum and dried, yield quantitative. 
2-N-[(3'-Carboxyl)propanoyl]-aminobenzophenone (7) 
On recrystallization from toluene mp. was 126-127 °C.IR: 3300, 2920, 1708, 1630, 
1595, 1576, 1510, 1445, 1412, 1318, 1265, 1178, 1160, 695 cm-1, NMR (CDC13) : 2.75/s, 4H), 
7.1-7.8 (m, SH), 8.72 (d, J=8 Hz), lH), 10.1 (broad s, lH, NH), 11.15 (8, lH, COOH). 
Anal: C17H 15N04 (297.32) calc'd.: C 68.67; H 5.08 ; N 4.729/o. 
found: C 68.74 ; H 5.28; N 4.730/o. 
2-N-[(3'-Carboxyl)propanoyl]-amino-5-chloro-benzophenone (6 ). 
On recrystallization from toluene mp. was 136-138 °c. IR: 3300, 2920, 1688, 
1630, 1595, 1575, 1505, 1395, 1320, 1245, 1160, 850, 755, 700 cm-1. NMR (CDC13), 2.74 
(s, 4H), 7.4-7.6 (m, 7H), 8.61 (d, J=8 Hz, lH), 10.5 (road s, lH, NH), 10.68 (s, lH, 
COOH). 
Anal: C11H14N04Cl (331.77) calc'd.: C 61.65; H 4.25; N 4.220/o. 
found: C 61.54; H 4.50; N 4.100/o. 
General Procedure for Preparation of N-aryl-succinimides 7 and 8. 
To the ice-cooled solution of compounds 5 or 6 (0.10 mole) in THF (250 ml), 
thionylchloride (13.0 g, 0.11 mole) was added dropwise, followed by 5 drops of DMF. 
After stirring for 24 hrs at ambient temperature, the solvent was evaporated and 
the residual oil treated with ether (50 ml), until crystallization was initiated. After 
chilling on ice, the crystals were collected on a filter, washed with ether (3 X 10 ml), 
and dried to afford 95-960/o of the crude product (one spot on TLC, Rr - 0.25 w ith 
dichlormethane-acetone 9.0 : 1.0 as eluant). 
N -(2' -Benzoy l )-phen y l-succinimide (7) 
On recrystallization from methanol mp. was 137-138 °C. IR: 1778, 1725, 1710, 
1665, 1600, 1485, 1465, 1380, 1315, 1300, 1288, 1175, 705 cm-1. NMR (CDC13): 2.48 (s, 
4H), 7.0-7.9 (m, 9H). 
Anal: C1H1 3N03 (279.30) calc'd. : C 73.11; H 4.69 ; N 5.010/o. 
found: C 73.16; H 4.68; N 4.96-0/o. 
N -(2' -Benzoy l-4' -chloro )pheny l-succinimide ( 8) 
On recrystallization from methanol mp. was 110-111°c. IR: 1780, 1725, 1670, 
1600, 1485, 1405, 1378, 1290, 1180, 710 cm-1. NMR (CDC13): 2.59 (s, 4H), 7.2-7.9 (m, 8H). 
Anal: C7H12N03Cl (313.75) calc 'd.: C 65.08 ; H 3.86; N 4.460/o. 
found: C 65.03; H 4.00; N 4. 720/o. 
General Procedure for Preparation of Compounds 9-11 
Compound 7 (837 mg, 3.0 mmol) and the corresponding amine (3.3 mmol ; L-pro-
line methylester hydrochloride32 was transformed into free base immediately before 
use) were dissolved in 5.0 ml of toluene (for condensation with piperidine, xylene 
was used), and heated under reflux for 4 h. 
2-N(3'-Benzylaminocarbonyl)-propanoyl-aminobenzophenone (9) 
On chilling on ice overnight crude 9 deposited as prismatic crystals, it was 
collected on a filter, washed with ether (2 X 2 ml) and dried, affording 647 mg 
(620/o). On recrystallization from methanol it had mp. 105-106 °c. IR : 3260, 3065, 
2900, 1720, 1650, 1635, 1600, 1585, 1550, 1518, 1450, 1250, 1165, 755, 735, 700, 640 cm·1• 
NMR (CDCl3), 2.62 (doublet t, 4H), 4.30 (d, J=5 Hz, 2H), 6.9-7.7 (m, 8H), 8.41 (d, lH), 
10.5 (s, lH, NH). 
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AnaL C24H22N20 3 (386.46) calc'd.: C 74.61; H 5.73; N 7.250/o. 
found: C 74.36; H 5.73; N 7.000/o. 
2-N(3' -Piperidylcarbonyl)propanoyl-aminobenzophenone (10) 
On evaporation of the solvent crude product was isolated by chromatography 
on a silica gel column (25 g) using methylene chloride-acetone (9.0 : 1.0) as eluant. 
Fractions 9-10 (10 ml/fraction) contained 790/o of product 10, which on crystallization 
from methanol melted at 130-131 °C. IR: 3310, 2980, 1680, 1668, 1620, 1530, 1485, 1450, 
1380, 1315, 1280, 1255, 1225, 1180, 925, 762, 710, 700 cm-1• NMR (CDCls): 1.48 (broad, 
6H), 2.66 (s, 4H), 3.32 (broad s, 4H), 6.7-7.6 (m, 8H), 8.42 (d, lH), 10.5 (s , lH, NH). 
AnaL: C22H24N20a (364.45) calc'd.: C 72.51; H 6.64; N 7.680/o. 
found: C 72.40; H 6.42; N 7.660/o. 
N-3-(2' -Benzoyl)phenyl-aminocarbonyl-propanoyl-L-proline-methylester (11) 
After evaporation of the solvent, the product mixture was separated on a silica 
gel column (30 g 60 cm x 1 cm) using methylene chloride-acetone (9.0 : 1.0) as eluent. 
In fractions 43-84 (5 ml/fraction) 51.40/o of 11 (oil) was isolated. An analytical sample 
was obtained by repeated chromatography. IR (film): 3300 (broad), 2950, 1725, 1695, 
1645, (multiplet), 1605, 1585, 1520, 1440, 1320, 1290, 1260, 1200, 1175, ?55, 700, 690 cm-1• 
NMR (CDC13): 2.0-2.15 (m, 4H), 2.77 (m, 4H), 3.69 (s, 3H), :3.6-3.8 (m, 2H), 4.51 (t, 
lH), 7.0-7.8 (m, 8H), 8.60 (dd, lH), 10.8 (s, lH, NH). 
AnaL: C23H 24N205 (408.43) calc'd.: C 67.63; H 5.92; N 6.860/o. 
found: C 67.44; H 6.07; N 6.760/o. 
By further elution with ethylacetate 75 mg of the cyclic dimer of L-proline, mp. 
173-175 °c (lit. 33 mp. 174-175 °C) was separated. 
N-3-(2' -Benzoyl)phenyl-aminocarbonyl-propanoyl-L-proline-benzylester (14) 
Method A. Starting from 7 (1.40 g, 5.0 mmole) and 2.66 g (11.0 mmole) of L-pro-
line benzylester hydrochloride preparation of 14 was performed as described for 
13. The crude product was separated on a silica gel column (120 g) using chloroform-
- acetone (9.2: 0.8) a eluant (1.66 g, 68.80/o)-glassy oil, [a]v = -14.0° (c = 0.88 in CHCb). 
Method B. Compound 5 (2.97 g, 10.0 mmole) was dissolved in chloroform (15 ml) 
and added dropwise to a solution of L-proline benzylester (free base from 2.66 g, 
11.0 mmole of hydrochloride), DCC (2.06 g 10.0 mmole), and imidazole (0.2 g), over 
15 min at o° C. Stirring was continued for 1 h at 0 °c, 4 h at ambient temperature, 
and then the reaction mixture was deposited on ice overnight. Dicyclohexylurea 
(DCU) that separated was filtered off (2.07 g, 92,50/o), the filtrate was evaporated 
and a sample (400 mg) was purified on a colum (30 g silica gel) using m ethylene 
chloride-acetone (9.2-0.8) as eluant. In the fractions 15-34 (10 ml/fraction) 317 mg 
of pure 14 was obtained, glassy oil, [a]v = -15.5 (c = 0.94 in CHCla). IR (film): 2930, 
1748, 1700, 1645, 1585, 1525, 1450, 1265, 1170, 755, 702 cm-1. NMR (CDC13): 2.0 (m, 
4H), 2.77 (m, 4H), 3.61 (m, 2H), 4.57 (t, lH), 5.16 (dd, 2H), 7.1-7.7 (m, 14H), 8.58 (d, 
lH), 10.8 (s, lH, NH). 
AnaL: C29H2aN20; (484.53) calc'd.: C 71.88; H 5.83; N 5.780/o 
found: C 71.96; H 5.57; N 5.660/o. 
N-3-(2' -Benzoyl-4' -chloro )phenyl-aminocarbonyl-propanoyl-L-proline-
-benzylster (15) 
This compound was prepared according to method B, described for 14, starting 
from 3.31 g (10.0 mmole) of 6. An analytical sample was obtained on repeated chro-
matography using methylene chloride-acetone (9.2: 0.8, Rt -0.35) as eluant. The 
pure product transformed into a glassy solid on prolonged drying in vacuo, over 
P205. [a]v = -12.6° (c = 1.4 in CHC13). IR (film) : 3310, 2950, 1745, 1695, 1600, 1580, 
1515, 1440, 1400, 1238, 1200, 1160-1180 (multiplet), 735, 705 cm-1• NMR (CDC13): 
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1.95-2.08 (m, 4H), 2.7-2.72 (m, 4H), 3.6 (m, 2H), 4.65 (m, lH), 5.74 (dd, 2H), 7.2-7.7 
(m, 13H), 8.55 (d, lH), 10.6 (s, lH, NH). 
Anal: C29H 27N20 5Cl (518.98) calc'd.: C 67.11; H 5.24; N 5.400/o. 
found: C 66.98; H 5.04; N 5.610/o. 
2-N-(3' -M ethoxycarbonyl)-propanoylamino-benzophenone (16) 
Compound 5 (838 mg, 3.0 mmole) was dissolved in abs. methanol (10.0 ml) and 
sodium methoxide (20 mg) was added. The reaction mixture was stirred for 3 hrs 
with exclusion of moisture. After adjusting the pH to 6.5 the solvent was evaporated, 
water (30 ml) was added, and the resulting slurry was extracted with chloroform 
(3 X 20 ml). Organic extracts were washed with water (2 X 20 ml) , dried and evapora-
ted to give 898 mg (960/o) of crude 16. After chromatography (30 g silica gel), using 
chloroform as eluant, pure 16 (610 mg) was obtained, glassy oil. IR: 3320, 2960, 1740, 
1705, 1640, 1610, 1588, 1525, 1450, 1320, 1295, 1160, 755, 640 cm-1• NMR (CDCla): 2.76 
(s, 4H), 3.69 (s, 3H), 7.0-7.7 (m, 8H), 8.62 (dd, lH), 10.0 (broad s, lH, NH). 
Anal: C18H 17N04 (311.32) calc'd.: C 69.44; H 5.50; N 4.500/o. 
found: C 69.63; H 5.56; N 4.320/o. 
N -3-(2-Benzoyl)phenyl-aminocarbonyl-propanoyl-L-proline (12) 
Method A. Compound 7 (279 mg, 1.0 mmole), imidazole (201 mg, 3.0 mmole), 
and L-proline (173 mg, 1.5 mmole) were homogenized and then heated with exclusion 
of moisture and with stirring at 90-95 °c. After 1 h the reaction mixture was allowed 
to cool to ambient temperature, water (10 ml) , and chloroform (10 ml) were added, 
and the pH adjusted with hydrochloric acid (1 : 1) to 1.5-2.0. The organic phase 
was separated, the aqueous phase was extracted with chloroform (3 X 10 ml) and 
the combined organic extracts were washed with water (2 X 20 ml) , dried and 
evaporated. The crude reaction mixture was purified on a silica gel column (25 g) 
using ethylacetate-methanol (7.0 : 3.0) as eluant. In fractions 10-38 (10 ml per 
fraction) 214 mg (54.50/o) of pure 14 was obtained, which resisted attempts of recry-
stallization. Due to the extreme hygroscopicity correct results could not be obtained 
for elemental analysis. [a)D = -55.8° (c = 1.02 in CHC13) . IR: 3100-3500 (broad), 
1645, 1605, 1520, 1445, 1260, 700 cm-1. NMR (MeOH-d4); 1.98 (m , 4H), 2.52 (dd, 4H), 
3.51 (m, 2H), 4.27 (t, lH) , 7.1-7.9 (m, 9H). 
Method B. Compound 14 (5.0 g, 10.3 mmole) was dissolved in 960/o ethanol 
(50 ml) , 800 mg of Pd/C was added and hydrogenolysis was performed in a closed 
system, until consumption of hydrogen ceased (ca. 5 hrs). The catalyst was filtered 
off, the organic solvent was evaporated to dryness and crude 12 was purified on a 
silica gel colum (110 g), eluted first with m ethylenechloride-acetone (9.2 : 0.8) and 
then with ethylacetate-methanol (1 : 1). 2.88 g (71 O/o) of pure 12 was obtained as a 
fine powder on addition of ether, [a ] v = -49.7° (c = 1.1 in CHC13). NMR and IR 
identical as for the sample obtained by the method A. 
N-3 -(2' -Benzoyl-4' -chloro )phenyl-aminocarbonyl -propanoyl-L-proline (13) 
Method A. Starting from 1.57 g (5.0 mmole) of compound 8, 1.70 g (25 .0 mmole) 
of imidazol, and 1.15 g (10.0 mmole) of L-proline, the reaction was performed at 
110- 125 °C for 1 h. Two products formed (Rt -0.75 and -0.05, methylene chloride-
-acetone 9.2 : 0.8). After elaboration as described for 12, the crude product mixture 
was separated on a silica gel colum (100 g) using first methylene chloride-acetone 
(9.2 : 0.8). In fractions 11-22 (10 ml/fraction) 343 mg of 
N-3-(2' -Benzoyl-4' -chloro )phenyl-aminocarbonyl-propanoyl-pyrolidine (17) 
were obtained. On crystallization from methanol it had mp. 148-151 oc IR: 3040-3300 
(multiplet), 2970, 1698, 1670, 1627, 1605, 1570, 1532, 1470. 1455, 850, 740, 700, 675 cm-1• 
NMR (CDCla): 1.75- 2.0 (m, 4H), 2.71 (double q, 4H), 3.37-3.52 (m, 4H), 7.4-7.8 (m, 
7H), 8.53 (d, lH}, 10.65 (s, lH, NH). 
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Anal: C21H 21N20 3Cl (384.85) calc'd.: C 65.53; H 5.50; N 7.28°/o. 
found: C 65.72; H 5.71; N 7.140/o. 
Further elution was performed with ethylacetate-methanol (6.0 : 4.0), affording 
1.046 g (490/o) of crude 17. A sample was purified by repeated chromatography with 
the same solvent system, dissolving in chloroform, washing with water, drying and 
evaporation. The amorphous powder that remained resisted attempts at recrystalli-
zation; correct results for elemental analysis could not be obtained. [a]v = -48.5° 
(c = 1.05 in CHCh). IR: 3300 (broad), 2980, 1630, 1600, 1570, 1510, 1480, 1450, 1285, 
1245, 700 cm-1• NMR (CDC13): 1.89 (m, 4H), 2.58 (broad s, 4H), 3.4 (m, 2H), 4.37 (m, 
lH), 7.2-7.7 (m, 7H), 8.18 (d, lH), 10.48 (s, lH, NH). 
Method B. Using identical conditions to those described for hydrogenolysis of 
14 into 12, compound 15 (729 mg, 2.0 mmole) was debenzylated into 13 (787 mg, 
920/o). [a]v = -47.6° (c = 0.97 in CHC13). IR and NMR spectra were identical to those 
of a sample obtained by method A. 
2-(3'-Carboxyl)propanoylamino-pyridin-N-oxide (18) 
Compound 18 (5.45 g, 40 mmole) was slurried in a mixture of 60 ml acetic acid, 
and 30 ml acetanhydride and 300/o aqueous hydrogen peroxide (35 ml) was added 
dropwise, with stirring at such a rate as to maintain the reaction temperature 
between 45-50 °c. Stirring at 50 °c was continued for 6 hrs, then the reaction mixture 
was deposited overnight on ice. The crude product (3.81 g, 64.50/o) was collected on 
a filter and recrystallized from methanol-acetic acid (1 : 1), affording pure 18, mp. 
204--206 °c. IR: 3260, 2500 and 1900 (two broad bands), 1710, 1580, 1505, 1240, 1200, 
1158, 1140, 810, 780, 725 cm-1• NMR (DMSO-d3): 3.36 (broad s, 4H), 7.02-7.5 (m, 2H), 
8.3-8.4 (double t, 2H), 10.56 (s, lH, NH). 
Anal: C9H1oN204 (210.18) calc'd.: C 51.43; H 4.80; N 13.330/o. 
found: C 51.14 ; H 5.00 ; N 13.260/o. 
2-Succinimido-pyridin-N-o:xd.de (21) 
Compound 19 (1.05 g, 5.0 mmole) w as slurried in acetanhydride (15.0 ml) and 
heated at 60 °c with stirring. After 30 min all solid went into solution. The 
bright- yellow solution was evaporated at 40 °c, leaving a red, oily residue. Ethyl-
acetate (5 ml) was added, and the solution deposited on ice for crystallization 
overnight. The crude product (396 mg) was collected on a filter, mother liquor~ 
were dilluted with ether (10 ml), affording an additional 160 mg of 21 (total yield 
556 mg, 590/o). On recrystallization from ethylacetate the pure product had mp. 
149-151 °C. IR: 3060, 1798, 1725, 1715, 1505, 1435, 1395, 1260, 1190, 935, 835, 775, 660 
cm-1, NMR (CDCh) : 2.8-3.2 (16 lines pattern of an AA'BB' system (CH2CH2) , a similar 
pattern was recently observed for N-(2 '-phenyl)phenylsuccinimide, and was investi-
gated for diastereotopy recognition34); 7.4 (m, 3H), 8.3 (m, lH). 
Anal: C9HsN20a (192.17) calc'd.: C 56.25; H 4.20; N 14.580/o. 
found: C 56.27; H 4.30; N 14.31°/o. 
N-3-(2'-Pyridyl)aminocarbonyl Propanoyl-L-proline-benzylester (24) 
Compound 18 (388.5 mg, 2.0 mmole) L- proline benzylester (532 mg, 2.2 mmole 
- free base), DCC (433 mg, 2.1 mmole), and imidazol (1.0 g, 15 mmole) were stirred 
in dry DMF (7 ml) at 0 °c, and then for 3 days at ambient temperature. DCU which 
separated was filtered off, solvent evaporated, and the residual oil partitioned between 
water (30 ml), and methylene chloride (4 X 20 ml). Dry organic extracts were evapo-
rated and the residue (837 mg) treated with warm ether. This brought to crystalli-
zation compound 26, i. e. 
N-N'-Dicyclohexyl-N-3-(2' -pyridyl)-aminocarbonyl-propanoyl-urea 
90 mg of crude product were obtained which on crystallization from methanol 
had mp. 176-178°C. IR: 3320, 3290, 2960, 2715, 1675, 1648, 1545, 1530 cm-1• NMR 
(CDCla): 1.26 and 1.79 (two broad m, 22H), 2.81 (s, 4H), 6.9-8.3 (m, 4H), 9.13 (s, lH, NH) . 
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Anal: C22Ha2N403 (400.51) calc'd.: C 65.97; H 8.05; N 13.99°/o. 
found: C 65.77; H 8.22; N 14.050/o. 
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Mother liquors were evaporated to dryness and eluted with chloroform-acetone 
(7.0: 3.0) from a silica gel column (35 g). In fractions 12-19 (10 ml/fraction) 228 mg 
(300/o) of pure 24 were obtained, glassy oil. [a] D = -71.6° (c = 0.95 in CHC13). IR (film): 
3270, 2930-2960 (m), 1745, 1695, 1640, 1580, 1530, 1435, 1305, 1170, 770, 740, 700 cm-1• 
NMR (CDCla): 2.0-2.2 (m, 4H), 2.73, 2.76 (dd, 4H) , 3.62 (m, 2H), 4.64 (m, lH), 5.12 
(dd, J = 12 Hz, 2H), 6.9-7.0 (m, lH), 7.30 (s, 5H), 7.5-7.7 (m, lH), 8.1-8.3 (m, 2H), 
9.58 (s, lH, NH). 
AnaL C21H23N304 (381.42) calc'd.: C 66.12; H 6.08; N 11.020/o. 
found: C 65.84; H 6.13 ; N 10.790/o. 
N-3-(1 '-0xy-2'-pyridyl)-aminocarbonyl-propanoyl -L-proline-benzylester (25) 
This compound was prepared from 23 (420.5 mg, 2.0 mmole) using the same 
molar ratios and reaction conditions as described for 24. The crude product mixture 
that was obtained on evaporation of extract was separated on a silica gel colum1) 
(35 g), using ethylacetate-methanol (7.0 : 3.0) as eluant. In fractions 3-6 (10 ml/fract-
ion) compound 27 emerged. 
N ,N-Dicyclohexyl-N-2-(1 '-oxy-2' -pyridyl)arninocarbonyl-propanoyl-urea (27) 
245 mg of the crude product was obtained, which on crystallization from 
methanol had mp. 162- 164°C. IR: 3350, 3230, 2940, 2860, 1700, 1682, 1655, 1620, 1575, 
1518, 1435, 1345, 1268, 1210, 765 cm-1. Nl\IIR (CDC13): 0.9-1.22 (m, 22H), 2.76 (dd, 4H), 
3.51 (broad s, lH, NH), 6.75- 6.85 (m, lH), 7.1-7.3 (m, lH), 8.05-8.30 (m, lH), 10.05 
(broad s, lH, NH). 
Anal: C22H32N40 4 (416.51) calc'd.: C 63.44; H 7.74; N 13.450/o. 
found: C 63.66; H 7.83; N 13.740/o. 
In fractions 7-11, 167 mg of the mixture 25/27 emerged, while fractions 12-36 
contained 347 mg of the pure 25. An analytical sample was purified by repeated 
chromatography using chloroform-acetone (7.0: 3.0) as the eluant (Rt -0.25 for the 
pure product). [a ] o = -82° (c = 1.05 in CHCla). IR (film): 3230, 2960, 1742, 1705, 
1645, 1568, 1506, 1425, 1270, 1205, 1165, 755, 698 cm-1• NMR (CDC13): 2.0-2.2 (m, 4H), 
2.75-2.95 (m, 4H), 3.6 (t, lH), 4.6 (m, lH), 5.15 (dd, 2H, J = 12 Hz) , 6.9 (m, lH), 
7.1-7.3 (m, 6H), 8.1-8.45 (m, 2H), 10.2 (broad s, lH, NH) . 
Anal: C21H23Na05 (397.42) calc'd.: C 63.46 ; H 5.830/o. 
found: C 63.21; H 6.040/o. 
N-3-(2'-Pyridyl)aminocarbonyl-propanoyl-r.-proline (22) 
Method A. Compound 20 (485 mg, 2.53 mmole) , L-proline (460 mg, 4.0 mmole), 
imidazole (340 mg, 5.0 mmole) , and DMF (0.5 ml) were mixed and placed in an 
oil-bath at 90-95 °c. After the mixture melted, stirring and heating were continued 
for 30 min. The reaction mixture was allowed to cool to ambient temperature, 5 ml 
of water were a dded, pH adjusted to 1.5-2.0, saturated with sodium chloride, and 
extracted with 5 X 10 ml of chloroform. Dried organic extracts were evaporated 
and the crude product (708 mg) was purified by chromatography (35 g silica gel), 
ethylacetate-methanol (6.0 : 4.0). In fractions 12-26 (10 ml/fraction) 592 mg (68°/u) 
of 22 were obtained, glassy residue, which was crystallized from methanol-ether, 
mp. 161-163 °c. [a]n = -86.3° (c = 1.2 in MeOH) . IR : 3250 (multiplet), 3150 (multiplet) 
2970, 1720, 1645, 1615, 1580, 1550, 1475, 1312, 1295, 1210, 1180, 1145, 1010, 785, 705 cm·1. 
NMR (CDC13): 2.14 (m, 4H), 2.7-2.8 (m, 4H) , 3.65 (dd, 2H), 4.48 (d, lH) , 7.03 (m, lH), 
7.6-7.8 (dt, lH) , 8.08 (d, lH), 8.29 (t, lH), 10.6 (broad s, lH, NH). 
Anal: C14H11Na04 (291.30) calc'd.: C 57.72 ; H 5.88; N 14.430/o. 
found: C 57.66; H 6.05 ; N 14.240/o. 
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Method B. Hydrogenolysis of compound 24 was performed as described for 
conversion of 14 into 12. The chromatographically pure product had mp. 160-163 °c, 
[a]v = -59.0° (c = 0.98 in MeOH). 
N-3~(1 '-Oxy -2' -pyridyl)aminocarbonyl-propanoyl-L-proline (23) 
Method A. Starting from 21 (576 mg, 3.0 mmole) acylation of L-proline was 
performed using the same conditions as described for 22. After evaporation of the 
organic extracts the crude product was crystallized from 2- propanol (608 mg, 660/o), 
mp. 106-108 °C. [a]D = -69.0° (c = 1.0 in MeOH). IR: 3570, 3450, 3290, 1725, 1648, 1615, 
1510, 1455 (m) , 1420, 1180, -810, 785 cm-1. NMR (DMSO-d6): 1.9 (m, 4H) 2.7 (m, 2H), 
3.5 (m, 4H) , 4.25 (t, lH), 7.03-7.50 (two double t , 2H), 8.31 (double t, J = 2 Hz, 2H), 
10.4 (s , lH, NH). 
Anal: C14H 17N30 5 X CH30H (339.35) calc'd.: C 53.09; H 6.23; N 12.380/o. 
found: C 52.99; H 6.00; N 12.270/o. 
Method B. Starting from· 25 compound 23 was obtained, as described for 12. 
[u.]v = -64.5° (c = 0.98 in MeOH). 
Determination of Inhibitory Activity 
Inhibitory activities of synthetized compounds were determined in vitro with 
porcine plasma angiotensin-converting enzyme (ACE, B grade, Calbiochem, Lucerne) 
using a fluorometric method and N-carbobenzoxy-L-pheny1alanyl-L-histidyl-L-leucine 
(Serva, Heidelberg) as the enzyme substrate.35 Reaction mixtures contained borax-
-phosphate buffer, pH 8.0, (prepared by titration of 0.05 M borax with 0.1 M KH2P04), 
1 O/o Na Cl, 1 X 10-4 M substrate, 35 ~1g/ml of the enzyme, inhibitors in different con-
centrations and up to 2.5°/o methanol, which served as the primary solvent for the 
substrate and inhibitors. The enzyme was preincubated with inhibitors or buffer 
alone for 15 min at 37 °C. The reaction was started by the addition of substrate, 
carried out at 37 °c for different time intervals up to 4 hours, and stopped by 
placing test tubes in a boiling water-batn for 5 min. To the cooled mixture 0.1 ml/ml 
of 2.56 M NaOH, 0.05 ml/ml of 0.0640/o o-phthaldialdehyde, and after 4 minutes 0.05 
ml/ml of 7.7 M HCl were added. The developed fluorescence was read after 30 min 
and after Millipore filtration on an Aminco-Bowman spectrofluorimeter. 
Reaction rates were ·linear during the indicated time interval. IC50 were calcu-
lated from the reaction rates obtained with inhibitor concentrations giving inhibition 
in the range of 30-650/o. With other enzymes only the effects of inhibitors at a 
concentration of 10-3 M were determined. 
For the determination of leucine am inopeptidase (hog kidney, 200 U/mg, Serva) 
hydrolysis of 2 X 10-3 M leucine-p-nitroanilide (Serva) in 0.1 M Tris-HCl buffer, pH 
8.6, supplemented with 5 X 10-3 M MgCh, was followed spectrophotometrically at 
410 nm. 
Activity of cathepsin B (bovine spleen, kind gift of P. Lo c n i k a r, »Jozef 
Stefan« Institute, Ljubljana) was measured with 4 x 10-4 M N-CBZ-L-arginyl-L-
-arginine-4-methoxy-2-naphthylamide (Serva) as substrate in 0.1 M Na,K-phosphate 
buffer, pH 6.0, with 10-3 M dithiothreitol (DTT) and 10-3 M EDTA.3~ 
For cathepsin H (bovine spleen, kind gift of P. Lo c n i k a r, »Jofof Stefan« 
Institute) and for a-chymotrypsin (bovine pancreas, 45 U /mg, Sigma, Saint Louis) 1 O/o 
azocasein (Serva) was used as substrate following the procedure described for 
cathepsin L.35 In the first case the buffer was 0.1 M Na-acetate, pH 6.0, with 10- 3 M 
DTT and EDTA, and in the second case 0.1 lVI Tris-HCl, pH 8.0, with 10- 3 M CaCh. 
Trypsin (bovine pancreas, Pliva, Zagreb) activity was measUi!ed photometri-
cally at 410 nm with 9.2 X 10-4 M benzoyl-u,L-arginine- p-nitroanilide (Boehringer, 
Mannheim) in 0.1 M Tris-HCl buffer, pH 8.2, with 10-3 M CaC12.37 
Elastase (porcine pancreas, 120 U/mg, Serva) activity was determined by radial 
diffusion in agar38 with 0.080/o elastin powder (Sigma) and 0.2 l\/I Tris-HCl buffer, 
pH 8.8. 
The enzymes, except leucine aminopeptidase, were incubated 10 min with 
inhibitor prior to the start of · the reaction. 
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SAZETAK 
Sinteza derivata N -[(3-supstituiranih)aminokarbonil]propanoil-L-prolina 
djelovanje na enzim za pretvorbu angiotenzina 
V. Sunjic, $. Simaga i Lj. Vitaie 
njihovo 
Opisana je priprava derivata N-(3-(hetero)aril-aminokarbonil]propanoil-L-pro-
lina, 12, 13, 22 i 23. Novi postupak sastoji se od taljenja (80-100 °C) N-(hetero)aril-
sukcinimida (7, 8, 20 i 21) sa nezasticenim L-prolinom i imidazolom u prisustvu 
dimetilformamida. In vitro odredivanje inhibicije enzima za pretvorbu angiotenzina 
(ACE) pokazalo je, da priredeni derivati N-(arilaminokarbonil)-propanoil-L-prolina 
imaju nizu aktivnost od captoprila (1). Koncentracije potrebne za 500/o-tnu inhibiciju 
kretale su se izmedu 2.5 x 10-4 i 3.3 X 10-3 M . 
